chartexchange

TriSalus: 3 Key Takeaways for Long-Term Investors

The Motley Fool | Nov 10, 2026 3:56 PM EST

On its third quarter of 2026 earnings call, held on Nov. 10, 2026, TriSalus (NASDAQ:TLSI) updated its full-year 2026 revenue guidance to $46 million to $48 million after reporting third-quarter revenue of $12.9 million. Sales team productivity delays and shifting treatment patterns disrupted short-term targets, testing management's ability to turn expanded clinical access into sustained growth. Three things management said stand out. Management doubled its sales force to capture a $2.5 billion market for pressure-enabled drug delivery (PEDD), a specialized catheter delivery system for liver tumors. New sales representatives in expansion territories required extra time to build physician relationships, causing third-quarter sales to miss internal targets. The Centers for Medicare and Medicaid Services (CMS), the federal agency governing healthcare reimbursement rates, finalized national pricing for outpatient procedures. This change gives the company a clear payment path across hospitals and an office-based lab (OBL), an outpatient clinical facility that offers faster patient scheduling. Continue reading

Read original article